Episurf Medical AB (publ) (EPIS-B.ST)
SEK 0.13
(-2.03%)
SEK 0.13
(-2.03%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -94.8 Million SEK | -26.1% |
| 2022 | -77 Million SEK | -10.95% |
| 2021 | -69.4 Million SEK | -8.61% |
| 2020 | -63.9 Million SEK | 7.12% |
| 2019 | -68.8 Million SEK | -19.65% |
| 2018 | -57.5 Million SEK | 5.97% |
| 2017 | -61.15 Million SEK | 0.9% |
| 2016 | -61.7 Million SEK | -40.33% |
| 2015 | -43.97 Million SEK | -32.21% |
| 2014 | -33.26 Million SEK | -42.88% |
| 2013 | -23.27 Million SEK | -42.8% |
| 2012 | -16.3 Million SEK | -227.25% |
| 2011 | -4.98 Million SEK | -79.31% |
| 2010 | -2.77 Million SEK | -413.97% |
| 2009 | -540.52 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -21.2 Million SEK | -292.59% |
| 2024 Q3 | -16.3 Million SEK | 23.11% |
| 2024 Q1 | -5.4 Million SEK | 73.0% |
| 2023 Q3 | -20.8 Million SEK | 28.03% |
| 2023 FY | -97.1 Million SEK | -26.1% |
| 2023 Q2 | -28.9 Million SEK | -24.57% |
| 2023 Q4 | -20 Million SEK | 3.85% |
| 2023 Q1 | -23.2 Million SEK | 1.69% |
| 2022 Q2 | -19.4 Million SEK | -19.02% |
| 2022 FY | -77 Million SEK | -10.95% |
| 2022 Q1 | -16.3 Million SEK | 13.76% |
| 2022 Q4 | -23.6 Million SEK | -34.86% |
| 2022 Q3 | -17.5 Million SEK | 9.79% |
| 2021 Q3 | -15.9 Million SEK | 9.66% |
| 2021 FY | -69.4 Million SEK | -8.61% |
| 2021 Q2 | -17.6 Million SEK | -5.39% |
| 2021 Q4 | -18.9 Million SEK | -18.87% |
| 2021 Q1 | -16.7 Million SEK | -1.21% |
| 2020 FY | -63.9 Million SEK | 7.12% |
| 2020 Q3 | -15.4 Million SEK | -6.94% |
| 2020 Q4 | -16.5 Million SEK | -7.14% |
| 2020 Q2 | -14.4 Million SEK | 19.55% |
| 2020 Q1 | -17.9 Million SEK | 3.76% |
| 2019 FY | -68.8 Million SEK | -19.65% |
| 2019 Q1 | -14.6 Million SEK | 3.31% |
| 2019 Q2 | -18.8 Million SEK | -28.77% |
| 2019 Q3 | -17.5 Million SEK | 6.91% |
| 2019 Q4 | -18.6 Million SEK | -6.29% |
| 2018 Q4 | -15.1 Million SEK | -19.84% |
| 2018 FY | -57.5 Million SEK | 5.97% |
| 2018 Q2 | -16 Million SEK | -15.94% |
| 2018 Q3 | -12.6 Million SEK | 21.25% |
| 2018 Q1 | -13.8 Million SEK | 11.04% |
| 2017 Q3 | -13.61 Million SEK | -4.78% |
| 2017 Q2 | -12.99 Million SEK | 31.76% |
| 2017 Q4 | -15.51 Million SEK | -13.96% |
| 2017 Q1 | -19.03 Million SEK | -2.93% |
| 2017 FY | -61.15 Million SEK | 0.9% |
| 2016 Q4 | -18.49 Million SEK | -22.95% |
| 2016 Q3 | -15.04 Million SEK | 8.74% |
| 2016 Q1 | -11.71 Million SEK | 17.14% |
| 2016 Q2 | -16.48 Million SEK | -40.69% |
| 2016 FY | -61.7 Million SEK | -40.33% |
| 2015 Q3 | -10.9 Million SEK | 4.17% |
| 2015 Q1 | -7.54 Million SEK | 6.85% |
| 2015 Q4 | -14.13 Million SEK | -29.62% |
| 2015 FY | -43.97 Million SEK | -32.21% |
| 2015 Q2 | -11.38 Million SEK | -50.91% |
| 2014 Q3 | -7.41 Million SEK | 21.03% |
| 2014 FY | -33.26 Million SEK | -42.88% |
| 2014 Q2 | -9.39 Million SEK | -12.49% |
| 2014 Q1 | -8.35 Million SEK | -32.44% |
| 2014 Q4 | -8.09 Million SEK | -9.16% |
| 2013 Q1 | -5.38 Million SEK | 10.33% |
| 2013 Q2 | -6.64 Million SEK | -23.6% |
| 2013 FY | -23.27 Million SEK | -42.8% |
| 2013 Q4 | -6.3 Million SEK | -27.55% |
| 2013 Q3 | -4.94 Million SEK | 25.65% |
| 2012 Q1 | -3.7 Million SEK | -84.59% |
| 2012 Q2 | -3.41 Million SEK | 7.78% |
| 2012 Q3 | -3.18 Million SEK | 6.56% |
| 2012 Q4 | -6 Million SEK | -88.16% |
| 2012 FY | -16.3 Million SEK | -227.25% |
| 2011 Q4 | -2 Million SEK | -62.07% |
| 2011 FY | -4.98 Million SEK | -79.31% |
| 2011 Q2 | -2.09 Million SEK | -192.69% |
| 2011 Q1 | -714.88 Thousand SEK | 13.0% |
| 2011 Q3 | -1.23 Million SEK | 40.88% |
| 2010 FY | -2.77 Million SEK | -413.97% |
| 2010 Q2 | -530.49 Thousand SEK | -20.57% |
| 2010 Q4 | -821.69 Thousand SEK | 16.48% |
| 2010 Q1 | -439.98 Thousand SEK | 0.0% |
| 2010 Q3 | -983.88 Thousand SEK | -85.47% |
| 2009 FY | -540.52 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | -22.239% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 131.537% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 131.537% |
| Arcoma AB | 4.66 Million SEK | 2134.335% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 28.145% |
| BICO Group AB (publ) | -618.3 Million SEK | 84.668% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 341.406% |
| CellaVision AB (publ) | 167.05 Million SEK | 156.749% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | -43.782% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | -220.578% |
| C-Rad AB (publ) | 44.24 Million SEK | 314.266% |
| Duearity AB (publ) | -25.76 Million SEK | -267.97% |
| Dignitana AB (publ) | -15.02 Million SEK | -530.906% |
| Getinge AB (publ) | 3.81 Billion SEK | 102.486% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | -38.504% |
| Iconovo AB (publ) | -45.77 Million SEK | -107.092% |
| Integrum AB (publ) | 6.51 Million SEK | 1555.698% |
| Luxbright AB (publ) | -25.8 Million SEK | -267.379% |
| Mentice AB (publ) | -679 Thousand SEK | -13861.708% |
| OssDsign AB (publ) | -91.95 Million SEK | -3.093% |
| Paxman AB (publ) | 12.61 Million SEK | 851.248% |
| Promimic AB (publ) | -9.11 Million SEK | -939.702% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 43.805% |
| SciBase Holding AB (publ) | -53.93 Million SEK | -75.754% |
| ScandiDos AB (publ) | -13.48 Million SEK | -603.108% |
| Sectra AB (publ) | 518.49 Million SEK | 118.284% |
| Sedana Medical AB (publ) | -65.54 Million SEK | -44.629% |
| Senzime AB (publ) | -133.74 Million SEK | 29.119% |
| SpectraCure AB (publ) | -21.35 Million SEK | -344.007% |
| Stille AB | 44.95 Million SEK | 310.892% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 97.359% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 346.195% |